Business Context and Reporting Period
Company: Banco Bradesco S.A. (Bank Bradesco)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2026
Accounting Standards: International Financial Reporting Standards (IFRS)
Bradesco reported its Q1 2026 results against a backdrop of a mixed Brazilian economy. While some sectors slowed due to restrictive monetary policy, the Central Bank of Brazil initiated an interest rate cut cycle, reducing the Selic rate from 15.00% to 14.75% in March 2026. The Bank projects GDP growth of 1.5% for 2026, down from 2.3% in the prior year. Key strategic developments include the consolidation of the health business under a new entity, "Bradsaúde S.A." (formerly Odontoprev), and significant advancements in AI-driven technology and digital channels.
Key Financial Metrics
| Metric (R$ thousands) | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Net Income (Parent Shareholders) | 5,177,940 | 5,604,829 | (7.6%) |
| Net Interest Income | 17,333,678 | 22,345,460 | (22.4%) |
| Fee and Commission Income | 7,880,686 | 7,301,544 | +7.9% |
| Operating Expenses | (26,613,345) | (24,143,172) | +10.2% (Increase) |
| Expected Credit Losses (Loans) | (7,585,330) | (7,454,827) | +1.8% (Increase) |
| Earnings Per Share (Common) | R$ 0.47 | R$ 0.50 | (6.0%) |
| Earnings Per Share (Preferred) | R$ 0.51 | R$ 0.56 | (8.9%) |
| Total Assets | 2,435,136,333 | 2,330,327,216 | +4.5% |
| Shareholders' Equity | 179,763,454 | 178,415,153 | +0.8% |
| Book Value Per Share | R$ 17.01 | N/A | - |
Balance Sheet Highlights (vs. March 2025)
- Total Deposits: R$ 752.2 billion (+20.8%). Time deposits grew 8.8%, while savings and demand deposits declined.
- Securities Portfolio: R$ 888.5 billion (+12.2%).
- Expanded Loan Portfolio: R$ 1,089.9 billion (+8.4%). Individual loans grew 9.5%; corporate loans grew 7.6%.
- Allowance for Loans: R$ 56.9 billion (+1.4%).
- Tier I Capital Ratio: 12.0%.
Material Changes vs. Prior Period
- Net Income Decline: Net income attributable to shareholders decreased by approximately 7.6% year-over-year, primarily driven by a 22.4% drop in Net Interest Income due to the interest rate environment and a 10.2% increase in operating expenses.
- Fee Income Growth: Non-interest income showed resilience, with Fee and Commission Income rising 7.9%, offsetting some of the decline in net interest margins.
- Capital Increase: Shareholders approved a capital stock increase to R$ 93.77 billion via capitalization of profit reserves.
- Dividend Policy: The Board approved an intermediary interest on equity payment of R$ 3.0 billion for Q1 2026, representing a payout ratio of approximately 68.27% of the adjusted calculation basis.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Economic Outlook: Management expects the Central Bank to continue cutting interest rates over the coming months. GDP growth is projected at 1.5% for 2026.
- Technology Strategy: The Bank is heavily investing in its "AI Powered" strategy. The proprietary "Bridge" AI platform has tripled initiatives to over 660 use cases. The Bank aims to increase the volume of business features delivered by 2.7x in 2026 compared to 2023.
- Health Business Restructuring: A major corporate reorganization is underway to consolidate the health business (Bradsaúde) into a single publicly listed entity, aiming to capture operational synergies.
Risks and Contingencies
- Geopolitical Risks: Intensified uncertainties regarding the conflict in the Middle East (Iran) and its potential impact on commodity prices (oil, fertilizers) and global inflation.
- Tax Reform: The enactment of Complementary Law No. 227/2026 regarding the Consumption Tax Reform (IBS/CBS) introduces new tax rates for financial services effective 2027-2033. The Bank states it is not yet possible to reliably measure the full impact.
- Legal Provisions: Significant provisions exist for tax risks (PIS/Cofins, INSS) and civil claims related to economic plans and inflation indexation. Total provisions for probable losses stood at R$ 17.8 billion as of March 31, 2026.
- Credit Risk: While the loan portfolio grew, the allowance for expected credit losses increased slightly. The Bank maintains a robust provisioning framework based on three stages of credit risk.
Investor Verification Checklist
- Interest Rate Sensitivity: Verify the impact of the ongoing Selic rate cuts on future Net Interest Income and the Bank's ability to maintain margins.
- Health Business Valuation: Review the details of the Bradsaúde restructuring and the valuation of the health assets being consolidated.
- Tax Reform Impact: Monitor the issuance of supplementary rules for the IBS/CBS tax reform to assess potential long-term profitability impacts starting in 2027.
- Expense Management: Analyze the drivers behind the 10.2% increase in operating expenses, particularly technology investments, to ensure they translate into efficiency gains.
- Capital Adequacy: Confirm that the Tier I Capital ratio (12.0%) and Basel Ratio (14.9%) remain well above regulatory minimums despite the capital increase and dividend payouts.